Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD sabatolimab - TIM3 antagonist Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04266301 STIMULUS-MDS2 (CMBG453B12301) Myelodysplastic syndrome Phase 3 500 Overall survival Sabatolimab 800 mg + azacitidine 75 mg/m2 Sabatolimab 800 mg + azacitidine 75 mg/m2 + placebo Patients with intermediate, high or very high risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) Target Patients Read-out Milesstone(s) 2023 Publication TBD 129 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation